Diabetology & Metabolic Syndrome最新文献

{"title":"Diabetes distress and associated psychosocial factors in type 2 diabetes. A population-based cross-sectional study. The HUNT study, Norway.","authors":"Hilde K R Riise, Anne Haugstvedt, Jannicke Igland, Marit Graue, Eirik Søfteland, Monica Hermann, Sofia Carlsson, Timothy C Skinner, Bjørn Olav Åsvold, Marjolein M Iversen","doi":"10.1186/s13098-025-01631-w","DOIUrl":"10.1186/s13098-025-01631-w","url":null,"abstract":"<p><strong>Background and aim: </strong>The world-wide prevalence of diabetes distress varies, and studies are mainly undertaken in clinical settings. By using data from the Trøndelag Health (HUNT) study, we aimed to estimate diabetes distress prevalence, its determinants, and associations with anxiety and depression among adults with type 2 diabetes.</p><p><strong>Methods: </strong>This population-based cross-sectional study consists of individuals ≥ 20 years with type 2 diabetes participating in the HUNT4 survey (2017-2019). Diabetes-distress prevalence with 95% confidence interval (CI) was calculated based on the five item Problem Areas in Diabetes (PAID-5) questionnaire. PAID-5 sum scores were rescaled to a 0-100 scale by multiplying the sum score by five. Linear and logistic regression models were used to examine associations of demographic, lifestyle- and clinical factors, with diabetes distress.</p><p><strong>Results: </strong>In total, 1954 individuals completed the PAID-5 questionnaire, with a mean score of 15.2 (SD 18.3) and 11.9% (95% CI 10.6-13.4) reporting high diabetes distress (PAID-5 ≥ 40). Multivariable linear regression showed that diabetes distress was associated with a 0.2 (95% CI 0.2-0.3) lower score for each year older age, 7.6 (95% CI 5.4-9.7) higher score for current insulin use, and 9.3 (95% CI 5.3-13.2) higher score for a history of diabetes foot ulcers. High levels of anxiety and depression symptoms were associated with higher diabetes distress (Anxiety: B 16.0, 95% CI 13.6-18.4, Depression: B 13.3, 95% CI 10.7-16.0).</p><p><strong>Conclusions: </strong>Diabetes distress is common and strongly associated with younger age at diabetes onset, insulin use, foot ulcer, and anxiety and depression symptoms. Identifying and addressing diabetes distress in diabetes follow-up may facilitate improving health outcomes and prevent more serious mental health issues in individuals with T2D. Nevertheless, the findings should be further examined in longitudinal studies.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"62"},"PeriodicalIF":3.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal associations between posttraumatic stress disorder and type 2 diabetes.","authors":"Yuqing Song, Ancha Baranova, Hongbao Cao, Weihua Yue, Fuquan Zhang","doi":"10.1186/s13098-025-01630-x","DOIUrl":"10.1186/s13098-025-01630-x","url":null,"abstract":"<p><p>Posttraumatic stress disorder (PTSD) patients have a high comorbidity with type 2 diabetes (T2D). Whether PTSD influences the risk of diabetes is still not known. We used GWAS data from European ancestry of PTSD (23,121 cases and 151,447 controls) and T2D (80,154 cases and 853,816 controls) to investigate the bidirectional associations between PTSD and T2D by the Mendelian randomization (MR) analysis. We showed that PTSD was causally associated with higher odds of T2D (OR = 1.04, 95% CI: 1.01-1.06, P = 0.0086), but not vice versa. Our study suggests that PTSD may increase the risk of T2D. PTSD sufferers should be screened for T2D and its precursor known as metabolic syndrome.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"63"},"PeriodicalIF":3.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated levels of PAI-1 precede the occurrence of type 2 diabetes mellitus.","authors":"Jenny Hernestål-Boman, Tina Öhman, Jan-Håkan Jansson, Marcus M Lind, Olov Rolandsson, Ingvar A Bergdahl, Lars Johansson","doi":"10.1186/s13098-025-01629-4","DOIUrl":"10.1186/s13098-025-01629-4","url":null,"abstract":"<p><strong>Aims: </strong>Plasminogen activator inhibitor-1 (PAI-1) is the main inhibitor of the fibrinolytic system and is mainly secreted from adipose tissue. It is associated with cardiovascular disease and has also been considered a possible early risk marker for type 2 diabetes. Here, we present the results of a large prospective study investigating PAI-1 levels in relation to incident type 2 diabetes mellitus.</p><p><strong>Methods: </strong>We conducted a prospective incident case-referent study within the Västerbotten Intervention Programme (VIP). Data on cardiovascular risk factors, fasting plasma glucose (FPG) and 2-hour plasma glucose (2-hPG) were collected at baseline health examination 1990-2005. Blood samples were collected and stored for future analyses. Participants were followed and 484 cases developed type 2 diabetes. Referents without type 2 diabetes were matched for sex, age, and year of participation, n = 484. Baseline plasma samples were analysed for PAI-1. Subgroup analysis was performed for 201 cases and 201 matched referents with normal baseline glucose levels (FPG < 6.1 and 2hPG < 8.9 mmol/L).</p><p><strong>Results: </strong>Elevated baseline levels of PAI-1 were associated with incident type 2 diabetes after adjustments for BMI, family history of diabetes, smoking status, hypertension, FPG and 2hPG (PAI-1; OR = 1.87, 95% CI: 1.06-3.29). A similar result was shown in the subgroup analysis with 201 participants who had normal glucose levels at time of the health examination (PAI-1; OR = 2.68, 95% CI: 1.03-6.95).</p><p><strong>Conclusions: </strong>Elevated PAI-1 levels in non-diabetic persons precede the manifestation of type 2 diabetes and can be detected before an elevation of FPG or 2-hPG is observed.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"61"},"PeriodicalIF":3.4,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation.","authors":"Maedeh Movahednasab, Hassan Dianat-Moghadam, Sana Khodadad, Reza Nedaeinia, Saeid Safabakhsh, Gordon Ferns, Rasoul Salehi","doi":"10.1186/s13098-025-01623-w","DOIUrl":"10.1186/s13098-025-01623-w","url":null,"abstract":"<p><p>Glucagon-like peptide-1 (GLP-1) is an incretin peptide hormone mainly secreted by enteroendocrine intestinal L-cells. GLP-1 is also secreted by α-cells of the pancreas and the central nervous system (CNS). GLP-1 secretion is stimulated by nutrient intake and exerts its effects on glucose homeostasis by stimulating insulin secretion, gastric emptying confiding the food intake, and β-cell proliferation. The insulinotropic effects of GLP-1, and the reduction of its effects in type 2 diabetes mellitus (T2DM), have made GLP-1 an attractive option for the treatment of T2DM. Furthermore, GLP-1-based medications such as GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, have been shown to improve diabetes control in preclinical and clinical trials with human subjects. Importantly, increasing the endogenous production of GLP-1 by different mechanisms or by increasing the number of intestinal L-cells that tend to produce this hormone may be another effective therapeutic approach to managing T2DM. Herein, we briefly describe therapeutic agents/compounds that enhance GLP-1 function. Then, we will discuss the approaches that can increase the endogenous production of GLP-1 through various stimuli. Finally, we introduce the potential of L-cell differentiation as an attractive future therapeutic approach to increase GLP-1 production as an attractive therapeutic alternative for T2DM.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"60"},"PeriodicalIF":3.4,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triglyceride glucose-waist circumference as a predictor of mortality and subtypes of cardiovascular disease: a systematic review and meta-analysis.","authors":"Mehrdad Rabiee Rad, Ghazal Ghasempour Dabaghi, Hossein Sadri, Bahar Darouei, Reza Amani-Beni, Sadegh Mazaheri-Tehrani","doi":"10.1186/s13098-025-01616-9","DOIUrl":"10.1186/s13098-025-01616-9","url":null,"abstract":"<p><strong>Background: </strong>The significant burden of cardiovascular diseases underscores the necessity for identifying novel predictive markers that can forecast both cardiovascular diseases and mortality. In recent years, TyG-obesity-related parameters have gained special attention in this regard. This study aimed to assess the association between TyG-waist circumference (TyG-WC) and cardiovascular diseases and mortality.</p><p><strong>Methods: </strong>A comprehensive search was performed in databases including PubMed, Scopus, and Web of Science from their inception until October 6, 2024. The key outcomes of interest included all-cause mortality, cardiovascular mortality, cardiovascular diseases, myocardial infarction, stroke, coronary artery diseases, peripheral artery diseases, and heart failure. The pooled risk ratio (RR) with corresponding 95% confidence intervals (CI) was calculated. Meta-analysis was carried out using StataMP 14.0.</p><p><strong>Results: </strong>A total of 17 studies were included in the analysis. The number of participants ranged between 2,224 and 95,342. The meta-analysis revealed that TyG-WC is significantly associated with an increased risk of all-cause mortality, cardiovascular mortality, cardiovascular diseases, myocardial infarction, stroke, coronary artery diseases, and peripheral artery diseases. However, only one study addressed the relationship between TyG-WC and heart failure with a positive correlation.</p><p><strong>Conclusion: </strong>This study indicates that TyG-WC could serve as a promising predictor of cardiovascular diseases, along with cardiovascular and all-cause mortality. Given its accessibility, TyG-WC may be a practical tool for screening purposes.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"59"},"PeriodicalIF":3.4,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between estimated glucose disposal rate and prediction of cardiovascular disease risk among individuals with cardiovascular-kidney-metabolic syndrome stage 0-3: a nationwide prospective cohort study.","authors":"Jing Tian, Hu Chen, Yan Luo, Zhen Zhang, Shiqiang Xiong, Hanxiong Liu","doi":"10.1186/s13098-025-01626-7","DOIUrl":"10.1186/s13098-025-01626-7","url":null,"abstract":"<p><strong>Background: </strong>Insulin resistance is a crucial factor in the development of cardiovascular diseases (CVD), yet the relationship between the estimated glucose disposal rate (eGDR), an index reflecting insulin resistance, and the risk of new-onset CVD among individuals with cardiovascular-kidney-metabolic (CKM) syndrome stage 0-3 remains underexplored, and large-scale prospective cohort studies are needed to clarify this relationship.</p><p><strong>Methods: </strong>All data for this study were extracted from the China Health and Retirement Longitudinal Study (CHARLS). The primary outcome was the incidence of new-onset CVD (including heart diseases (HD) and stroke) during the follow-up period (from 2013 to 2020). Multivariable logistic regression models were applied to elucidate the relationship between the eGDR and the risk of developing CVD. The restricted cubic splines (RCS), mediation analysis, and stratified analyses were also employed.</p><p><strong>Results: </strong>This study included 6752 participants, of whom 1495 (22%) developed CVD. Odds ratios and 95% confidence intervals from lowest eGDR level (<7.37 mg/kg/min) to highest eGDR level (≥ 11.16 mg/kg/min) were 1.00 (reference), 0.81 (0.68, 0.96), 0.72 (0.58, 0.88), and 0.74 (0.58, 0.94) respectively, for the occurrence of CVD; 1.00 (reference), 0.81 (0.67,0.97), 0.72 (0.57,0.90), and 0.75 (0.58,0.97) respectively, for the occurrence of HD; 1.00 (reference), 0.91 (0.74,1.12), 0.80 (0.62,1.04), and 0.71 (0.52,0.97) respectively, for the occurrence of stroke after adjusting for all potential covariates. The RCS analysis discovered an approximately inverse \"L\" correlation between eGDR and the occurrence of CVD and HD across all individuals with CKM syndrome stages 0-3 (All P for overall < 0.001, All P for nonlinear = 0.005), while there was a negative linear correlation between eGDR and the risk of new-onset stroke (P for overall = 0.026, P for nonlinear = 0.098). Furthermore, the proportions mediated through BMI were 41.98%, 43.05%, and 43.23% for CVD, HD and stroke, respectively. No significant interactions were found.</p><p><strong>Conclusions: </strong>The eGDR was a novel indicator of new-onset CVD in individuals with CKM syndrome stages 0-3, with BMI serving as a partial mediator in the association between eGDR and CVD risk. Addressing insulin resistance may represent a viable strategy for reducing the risk of CVD in this population.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"58"},"PeriodicalIF":3.4,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CircRNA-mediated ceRNA regulatory networks: transcriptomic insights into obesity type 2 diabetes progression and treatment strategies.","authors":"Xian-Jie Zhen, Ren-Tong Hu, Nan-Nan Liu, Jin-Fang Dou, Tao Wu, Yue-Lin Zhang, Chu-Yue Zhang, Li Ma, Guang-Jian Jiang","doi":"10.1186/s13098-025-01578-y","DOIUrl":"10.1186/s13098-025-01578-y","url":null,"abstract":"<p><p>The aim of this study was to deeply explore the pathogenesis of obesity type 2 diabetes mellitus (O-T2DM) and search for potential biomarkers through high-throughput RNA sequencing technology. The study included 15 patients with O-T2DM and 15 healthy controls, and peripheral blood samples were collected for transcriptome analysis. The results showed that compared with the control group, there were 442 circRNAs and 2756 mRNAs with significant differential expression in the O-T2DM group. Through weighted gene co-expression network analysis (WGCNA) and pathway enrichment analysis, it was found that the differentially expressed mRNAs were mainly enriched in signaling pathways such as T cell receptor, cell senescence, cytotoxicity mediated by NK cells, IL-17, lipids and atherosclerosis, and the oxidative phosphorylation pathway was activated, and apoptosis was inhibited. Based on the ceRNA theory, a regulatory network was constructed, and key circRNAs such as hsa_circ_0060614 were screened out, which may regulate the expression of the MT2A gene by adsorbing hsa-mir-4668-3p, and the expression levels of the three were significantly increased in O-T2DM patients. This study provides a new perspective for the research on the molecular mechanism of O-T2DM and an important theoretical basis for the development of personalized treatment and precision medicine for it.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"57"},"PeriodicalIF":3.4,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-glycaemic effect of the Chinese modified DASH diet combined with 23% low-sodium salt in patients with hypertension and type 2 diabetes: a clinical trial.","authors":"Jiaxian An, Guowei Liu, Wenjun Luo, Xiaomeng Zhou, Ying Mei, Ziyan Zhang, Li Zhao, Yao Huang, Lihong Mu","doi":"10.1186/s13098-025-01618-7","DOIUrl":"10.1186/s13098-025-01618-7","url":null,"abstract":"<p><strong>Background: </strong>Although many previous trials have formalized the blood glucose-lowering effect of the DASH diet, relevant reports in China remain limited. This study aimed to explore the anti-hyperglycaemic effect of the Chinese Modified Dietary Approaches to Stop Hypertension diet combined with 23% low-sodium salt and meal packs in patients with hypertension and type 2 diabetes.</p><p><strong>Methods: </strong>We conducted a randomized controlled single-blinded trial with a semi-open design; 100 participants were randomly assigned to Group A (control), Group B (23% low-sodium salt), and Group C (meal packs) for 8 weeks of dietary intervention. All participants were followed up weekly to collect glycaemia data (standardized meal tolerance test), salt use, and adverse events.</p><p><strong>Results: </strong>Generalized estimating equation analysis indicated that fasting blood glucose decreased in all three groups following the intervention when compared to baseline. Group A decreased by 0.72 mmol/L (P = 0.008), while Groups B and C decreased by 2.02 mmol/L and 2.06 mmol/L, respectively (both P < 0.001). Although the latter two groups experienced greater reductions than Group A, the differences among the groups were not statistically significant (P = 0.450). For postprandial blood glucose, Group C showed the most pronounced decrease. The three groups recorded reductions of 2.43 mmol/L, 2.52 mmol/L, and 4.29 mmol/L, respectively (all P < 0.001), with again no significant difference observed between the groups (P = 0.088). The most notable enhancement in postprandial glucose was observed in Group C, which demonstrated a 51.5% improvement in its control rate. However, there was no statistically significant difference between the groups. No serious adverse events occurred during the trial.</p><p><strong>Conclusion: </strong>The CM-DASH diet combined with 23% low-sodium salt and meal packs demonstrates potentially beneficial effects on glycemic control in patients with hypertension and type 2 diabetes. This intervention reduces salt intake and fosters the development of healthy eating habits, thereby contributing to the improvement of patients' blood glucose. However, larger studies are necessary to confirm these findings. Trial registration ChiCTR2000029017. Registered January 11, 2020-Prospective registration, http://www.chictr.org.cn/.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"55"},"PeriodicalIF":3.4,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11823202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fifteen-year trends in diabetes drug management and control in French-speaking Switzerland.","authors":"Ariane Pauli, Abdullah Alkandari, Pedro Marques-Vidal","doi":"10.1186/s13098-025-01620-z","DOIUrl":"10.1186/s13098-025-01620-z","url":null,"abstract":"<p><strong>Objective: </strong>Drug management of type 2 diabetes (T2D) should comply with established guidelines. Still, little is known about how drug management of T2D in Switzerland has evolved over time. We aimed at assessing 15-year trends in antidiabetic drug prescription and its effectiveness in reducing fasting plasma glucose (FPG) levels.</p><p><strong>Research design and methods: </strong>Data from the baseline (2003-2006) and three follow-ups (2009-2012, 2014-2017 and 2018-2021) of a population-based study conducted in Lausanne, Switzerland. Participants treated for T2D were included. At baseline and the follow-ups, participants had their antidiabetic drugs collected, together with their FPG and glycated haemoglobin (HbA₁c) levels.</p><p><strong>Results: </strong>There were 274, 280, 268 and 195 participants treated for T2D at the baseline, first, second and third follow-ups, respectively, of whom 101 (36.9%), 103 (36.8%), 138 (51.5%) and 84 (43.1%) were controlled (FPG < 7 mmol/L). During the study period, the percentage of biguanides remained stable, the percentage of sulfonylureas and thiazolidinediones decreased, and the percentage of SGLT2 and DPP4 inhibitors increased, but no consistent association with T2D control was found. On bivariate and multivariable analysis, participants with newly diagnosed T2D had a higher likelihood of being controlled than participants with established T2D: odds ratio (95% CI) 3.39 (1.89-6.07), 5.41 (2.25-13.0) and 3.47 (1.45-8.31) for the first, second and third follow-ups on multivariable analysis, respectively.</p><p><strong>Conclusions: </strong>Despite the prescription of novel antidiabetic drugs, half of participants treated for diabetes do not achieve adequate control in Switzerland. Participants with newly diagnosed diabetes achieve much better control than participants with established diabetes.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"56"},"PeriodicalIF":3.4,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11823013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-density lipoprotein cholesterol predicts coronary artery calcification events in patients with type 2 diabetes: a longitudinal study.","authors":"Zhi Zou, Yongbing Sun, Lijun Zou, Yang Zhou, Xinbei Lin, Jing Zhou, Zhonglin Li, Xiaoling Wu, Ling Wang, Xiaodong Li, Yong Wang, Yangxi Hu, Fengli Li, Jiancheng Zhang, Yongli Li","doi":"10.1186/s13098-025-01625-8","DOIUrl":"10.1186/s13098-025-01625-8","url":null,"abstract":"<p><strong>Background: </strong>Coronary Artery Calcification (CAC) is a major risk factor for various cardiovascular diseases. Low-Density Lipoprotein Cholesterol (LDL-C) is a significant factor in atherosclerotic cardiovascular diseases and is usually elevated in patients with Type 2 Diabetes Mellitus (T2DM). However, the association between LDL-C levels and incident CAC in asymptomatic T2DM patients remains unclear.</p><p><strong>Methods: </strong>This study is a single-center retrospective cohort study conducted from January 2018 to December 2023, including 2,631 asymptomatic T2DM patients who underwent regular health screenings. All participants were confirmed to be free of CAC at baseline by computed tomography (CT). Based on baseline LDL-C levels, participants were divided into three groups (T1: 0.66-2.43 mmol/L; T2: 2.44-3.18 mmol/L; T3: 3.19-7.21 mmol/L). The follow-up endpoint was the occurrence of incident CAC, with a total follow-up period of 72 months. Kaplan-Meier survival curves were used for analysis, followed by log-rank tests. Univariate and multivariate Cox proportional hazards regression models were employed to investigate the relationship between LDL-C and incident CAC, and subgroup analysis was performed to test the robustness of the LDL-C and CAC relationship.</p><p><strong>Results: </strong>During a median follow-up period of 29.9 months, 885 (33.64%) participants developed incident CAC occurred. The cumulative incidence of incident CAC increased progressively with higher LDL-C levels (log-rank test, P < 0.001). After adjusting for confounding factors, multivariable Cox proportional hazards regression results showed a significant association between LDL-C and incident CAC (hazard ratio [HR], 1.77; 95% confidence interval [CI], 1.64-1.92). When LDL-C was treated as a categorical variable, elevated levels in T2 (adjusted HR, 1.62; 95% CI, 1.36-1.93; P < 0.001) and T3 (adjusted HR, 3.38; 95% CI, 2.84-4.03; P < 0.001) were significantly associated with the risk of incident CAC. Additionally, subgroup analysis demonstrated a consistent association between LDL-C and incident CAC.</p><p><strong>Conclusion: </strong>High LDL-C levels are associated with incident CAC in asymptomatic T2DM patients, suggesting that LDL-C may be useful for risk stratification in this population.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"53"},"PeriodicalIF":3.4,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11823151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}